peak glp 1 Funnel plot for GLP-1 publication bias SMA
Description
On week, three, and Ive already lost 9 pounds
DPP-4i extends the half-life of GLP-1, thereby enhancing insulin production and diminishing glucagon release, which leads to improved glycemic control in individuals with type 2 diabetes mellitus (T2DM) [9]
Jayaram H, Kolko M, Friedman DS, Gazzard G
doi: 10.1016/j.molmet.2017.02.002 37 KnerrPJMowerySADourosJDPremdjeeBHjollundKRHeYet al
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: A novel cardiometabolic therapeutic prospect
Side Effects and Safety Profile Common side effects are mostly gastrointestinal and dose-dependent, including nausea, vomiting, diarrhea, constipation, and decreased appetite
